Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 5Leukemia, Myelomonocytic, Chronic 4Leukemia 4Anemia, Refractory, with Excess of Blasts 3Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Hematologic Diseases 2Blast Crisis 2Preleukemia 1Neutropenia 1Myeloproliferative Disorders 1Anemia, Refractory 1

Interventions

Cyclophosphamide 27Cyclosporine 22fludarabine phosphate 21Busulfan 19Peripheral Blood Stem Cell Transplantation 16Antilymphocyte Serum 16Radiotherapy 15Mycophenolic Acid 15Cord Blood Stem Cell Transplantation 15Whole-Body Irradiation 13Methotrexate 11Methylprednisolone 10Filgrastim 9Cytarabine 7Tacrolimus 6Melphalan 6Etoposide 6sargramostim 4fludarabine 4Thiotepa 4Decitabine 4Azacitidine 4Granulocyte Colony-Stimulating Factor 3Cyclosporins 3Arsenic Trioxide 3merphos 2Vorinostat 2Topotecan 24-phenylbutyric acid 2vatalanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia, Refractory × lintuzumab × Myeloid × Clear all
NCT00997243 2017-05-10

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

Ohio State University Comprehensive Cancer Center

Phase 2 Terminated
7 enrolled 8 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡